Table 2.

Summary of the studies examining clonal hematopoiesis in cancer patients

Source	Population	Seq method	Findings
Coombs et al 2017	8,810 individuals with non-hematologic cancers	Whole exome sequence Paired (Blood and cancer)	25% of patients had CH. 4.5% of patients had CH-PD. CH was associated with increased age, prior radiation therapy, and tobacco use. CH-PD was associated with diminished patient survival.
Gibson et al, 2017	12 NHL patients before ASCT 401 NHL patients after ASCT	Whole exome sequence Targeted-NGS for 86 genes	29.9% of patients have CHIP. CHIP was associated with inferior survival from tMN and CVD.
Kahn et al, 2018	401 NHL patients 28,418 individuals unselected for cancer	Whole exome sequence Targeted-NGS	PPM1D mutations were 60 times more prevalent in chemotherapy-exposed NHL patients.
Bolton et al, 2020	24,146 cancer patients (56 types of primary tumor)	Deep targeted amplicon sequence	30% of patients had CH. Cancer treatment was associated with CH with enrichments in DDR genes (PPM1D, TP53, CHK2).
Miller et al, 2021	154 NHL or MM patients receiving CAR T-cells	NGS of the driver genes	48% of patients had CHIP. CHIP was associated with increased CR rate and CRS severity.

CH-PD: clonal hematopoiesis of putative driver genes, NHL: non-Hodgkin lymphoma, ASCT: autologous stem-cell transplantation, NGS: next-generation sequencing, tMN: therapy-related myeloid neoplasms, CVD: cardiovascular disease, MM: multiple myeloma, CR: complete response, CRS: cytokine release syndrome